Across the world, traffic accidents cause major health problems and are of concern to health institutions; nearly 1.35 million people are killed or disabled in traffic accidents every year. In 2019, 93% of road traffic injury‐related mortality occurred in low‐ and middle‐income countries with an estimated burden of 1.3 million deaths. This issue is growing; by 2030, road traffic injuries will be the seventh leading cause of death globally. The present report highlights an overview of road traffic accidents, accidental injuries, and deaths, associated risk factors, important precautions, safety rules, and counteracting management strategies. In modern cultures, road accidents are a major source of death and serious injuries. Road traffic injuries are a substantial yet underserved public health issue around the world that requires immediate attention. To prevent accidents in the long term, it is essential to adopt conservative preventive measures that can minimize collisions and promote a safe road environment.

The World Health Organization (WHO) proclaimed a public health emergency in July 2022 due to the emergence of Mpox (formerly monkeypox) while the globe was still dealing with the COVID-19 epidemic. The characteristics of mpox in immunocompetent individuals are well-characterized, despite difficulties in diagnostics, immunization, and access to treatment that persist in low-income countries. Patients with weakened immune systems are more likely to spread an illness and die from it than healthy people because they cannot mount a protective immune response against it, such as a neutralizing IgG and poxvirus-specific Th1 response. A health warning on severe mpox in people who are immunocompromised due to Human Immunodeficiency virus (HIV) and other illnesses was released by the U.S. Centers for Disease Control and Prevention (CDC) on September 29, 2022. The advice does not specifically include primary immunodeficiency, but it does define other immunocompromising disorders as “having autoimmune disease with immunodeficiency as a clinical component”. Both those with healthy immune systems and those with weakened immune systems, such as those who are immunosuppressed, older people, children, etc., have encountered serious health issues, but the latter group is more likely to do so. According to the advisory, “of the people with severe mpox manifestations for whom CDC has been consulted, the majority have had HIV with CD4 counts 200 cells/ml, indicating substantial immunosuppression”. However, new cases are still expected to be discovered, especially in low-income countries with limited access to diagnosis, treatment, and prevention, and where a large percentage of the mpox-infected population also has advanced HIV infection. Thus, further research is always needed to determine the best way to treat mpox in immunocompromised people. In this context, we discussed /reviewed the mpox clinical presentation, available treatment options and current preventive guidelines in immunocompromised patients.

Background: Adopting generative artificial intelligence (GenAI) in education rapidly transforms learning environments, yet nursing students’ acceptance and anxiety toward these technologies remain underexplored in Middle Eastern contexts. This study extends the Technology Acceptance Model (TAM) by incorporating constructs such as Facilitating Conditions (FC) and Social Influence (SI). It investigates the moderating role of Anxiety on Behavioral Intention to Use (BIU) generative AI tools. Methods: A cross-sectional study was conducted among 1,055 undergraduate nursing students across four Middle Eastern countries, including Egypt, Jordan, Saudi Arabia, and Yemen. Data were collected using a structured questionnaire comprising the Generative Artificial Intelligence Acceptance Scale and the Artificial Intelligence Anxiety Scale. Structural equation modeling was employed to evaluate relationships among Performance Expectancy (PE), Effort Expectancy (EE), FC, SI, and BIU, with Anxiety as a moderator. Descriptive statistics, confirmatory factor analysis, and path analysis were performed using SPSS and Python’s semopy library. Results: The model demonstrated strong explanatory power, with 75.09% of the variance in BIU explained by the TAM constructs and Anxiety. Path coefficients revealed significant positive relationships between PE (β = 0.477, p < 0.001), EE (β = 0.293, p < 0.001), FC (β = 0.189, p < 0.001), and SI (β = 0.308, p < 0.001) and BIU. Anxiety had the strongest moderating effect (β = 0.552, p < 0.001), indicating its critical role in shaping behavioral intentions. Gender, year of study, and access to technology emerged as significant demographic variables influencing acceptance and anxiety levels. Conclusions: This study emphasizes the importance of reducing anxiety and enhancing support systems to foster GenAI acceptance among nursing students. The findings provide actionable insights for designing culturally tailored educational interventions to promote the effective integration of AI in nursing education. Clinical trial number: Not applicable.

The recent spread of the monkeypox virus (MPXV), causing monkeypox (mpox), to non-endemic areas, and the atypical and unusual clinical manifestations observed during its 2022 outbreak has focused international interest on the clinical features of the disease. Mpox is usually a self-limiting disease with mild symptoms with common manifestations, including fever and skin lesions; however, severe manifestations could occur in some vulnerable groups (children and those with impaired immune systems) and may present multisystem complications and fatal outcomes. In most cases, a fever is the first sign of disease, followed by the development of various inflammatory lesions on the skin, such as vesiculopustular rashes and ulcers. Pneumonitis, encephalitis, keratitis, secondary bacterial infections, acute kidney injury, and myocarditis are all possible outcomes of the infection. Myocarditis has been reported to be caused by orthopoxviruses, and it is a serious condition of which its pathophysiology is little understood. Recent reports have indicated myocarditis with cardiac involvement as a possible atypical and unusual consequence of the MPXV infection during present outbreak. This review provides an overview of the clinical manifestations of mpox with a special focus on its effects on the heart, including myocarditis. The evidence of the myocarditis in mpox patients and its possible pathogenesis are discussed.